Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel tetramerization domain-containing protein 20 (KCTD20) is a member of the KCTD family, characterized by a conserved N-terminal BTB (Bric-à-brac, Tram-track, Broad complex) domain that mediates protein-protein interactions and often functions as an adaptor for Cullin3-based E3 ubiquitin ligase complexes[2][3]. Unlike classical ion channels, KCTD20 does not constitute a potassium channel but shares homology with the tetramerization domain (T1) found in voltage-gated potassium channels, which determines oligomerization specificity[1][2]. KCTD20 is predicted to promote phosphorylation of AKT family members and is involved in cytoplasmic signaling processes, with localization to the cytoplasm and association with the cell membrane[3]. The protein is implicated in the pathogenesis of certain neurodegenerative diseases, such as progressive myoclonus epilepsy, but its precise biological roles and potential as a drug target are largely uncharacterized[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium channel tetramerization domain-containing protein 20 (KCTD20).